Cargando…

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Wei-Gang, Polotskaia, Alla, Xiao, Gu, Di, Lia, Zhao, Yuhan, Hu, Wenwei, Philip, John, Hendrickson, Ronald C., Bargonetti, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319483/
https://www.ncbi.nlm.nih.gov/pubmed/28232952
http://dx.doi.org/10.1038/s41523-016-0001-7
_version_ 1782509388237373440
author Qiu, Wei-Gang
Polotskaia, Alla
Xiao, Gu
Di, Lia
Zhao, Yuhan
Hu, Wenwei
Philip, John
Hendrickson, Ronald C.
Bargonetti, Jill
author_facet Qiu, Wei-Gang
Polotskaia, Alla
Xiao, Gu
Di, Lia
Zhao, Yuhan
Hu, Wenwei
Philip, John
Hendrickson, Ronald C.
Bargonetti, Jill
author_sort Qiu, Wei-Gang
collection PubMed
description Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2–7. To validate this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2–7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics.
format Online
Article
Text
id pubmed-5319483
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-53194832017-02-21 Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer Qiu, Wei-Gang Polotskaia, Alla Xiao, Gu Di, Lia Zhao, Yuhan Hu, Wenwei Philip, John Hendrickson, Ronald C. Bargonetti, Jill NPJ Breast Cancer Article Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2–7. To validate this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2–7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics. Nature Publishing Group UK 2017-01-19 /pmc/articles/PMC5319483/ /pubmed/28232952 http://dx.doi.org/10.1038/s41523-016-0001-7 Text en © The Author(s) 2017 This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Qiu, Wei-Gang
Polotskaia, Alla
Xiao, Gu
Di, Lia
Zhao, Yuhan
Hu, Wenwei
Philip, John
Hendrickson, Ronald C.
Bargonetti, Jill
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_full Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_fullStr Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_full_unstemmed Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_short Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_sort identification, validation, and targeting of the mutant p53-parp-mcm chromatin axis in triple negative breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319483/
https://www.ncbi.nlm.nih.gov/pubmed/28232952
http://dx.doi.org/10.1038/s41523-016-0001-7
work_keys_str_mv AT qiuweigang identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT polotskaiaalla identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT xiaogu identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT dilia identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT zhaoyuhan identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT huwenwei identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT philipjohn identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT hendricksonronaldc identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
AT bargonettijill identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer